Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera peutic proteins for global markets. The company has two commer cialized products, Elelyso that is marketed by Fiocruz in Brazil & Pfizer in the rest of the world for Gaucher Disease and Elfabrio which was approved in May 2023. Chiesi Rare Disease will commercialize Elfabrio globally. Protalix has additional candidates in earlier stages of development in cluding PRX-115 for the treatment of refractory gout and PRX-119, a long action DNase I for the treatment of NETs-related diseases. Elfabrio was approved in Europe and the United States in early May 2023 and continues to be approved elsewhere. The product can fill an unmet need with several im provements over the market leader and is expected to command a premium vs. existing prod ucts. Elelyso should show moderate growth over the next quar ters as partners continue their commercializa tion efforts. Profits from revenue generating products are expected to be invested in new candi dates in coming years.